v3.26.1
Segment Information (Tables)
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Schedule of Segment Reporting
The Company had revenue of $0 and $0 for the three and six months ended June 30, 2026, respectively, and $70 thousand and $70 thousand for the three and six months ended June 30, 2025, respectively. Depreciation and amortization expense was $3 thousand and $5 thousand for the three and six months ended June 30, 2026, respectively and $44 thousand and $87 thousand for the three and six months ended June 30, 2025, respectively. The following table illustrates our segment information for significant operating expenses and includes a reconciliation to net loss for the three and six months ended June 30, 2026 and 2025:

Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Revenue$— $70 $— $70 
Operating Expenses:
Research and development by significant expense:
  BOLSTER trial$(270)$605 $(320)1,393 
  ASCEND trial27 32 201 53 
  Chemistry, manufacturing and controls199 167 390 387 
  Clinical department586 991 1,354 2,148 
  Other (1)
42 458 162 875 
Research and development584 2,253 1,787 4,856 
General and administrative by significant expense:
  Corporate1,483 1,157 2,816 2,302 
  Investor relations/public relations/communications214 309 451 640 
  Finance598 538 1,183 1,167 
  Legal760 327 1,854 551 
  Business development156 140 305 267 
  Share based compensation expense178 212 471 616 
  Other (2)
19 2 66 387 
General and administrative3,408 2,685 7,146 5,930 
Operating loss(3,992)(4,868)(8,933)(10,716)
Other income, net1,063 209 1,128 371 
Benefit from income taxes— — (387)(962)
Net loss$(2,929)$(4,659)$(7,418)$(9,383)
Cash and marketable securities$10,443 $21,970 
 (1) Included in Other are the GBM study, FORTIFIDE study and research
     oncology expenses
 (2) Included in Other are facilities expense, human resource
     and information technology expenses